Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3932386 | 0.80 | HTR2C (0.53) | HTR2CSMN1; SMN2NPC1RAB9ACACNA1G | |
| SCHEMBL6629621 | 0.80 | HTR2C (0.45) | HTR2CMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL6630038 | 0.79 | HTR2C (0.44) | ALDH1A1HTR2CSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6629318 | 0.76 | HTR2C (0.51) | HTR2CMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL6625379 | 0.76 | KCNH2 (0.43) | ALDH1A1HTR2CMEN1KMT2A | |
| SCHEMBL31295228 | 0.72 | HTR2C (0.50) | HTR2CSMN1; SMN2NPC1RAB9A | |
| SCHEMBL14336080 | 0.71 | HTR2C (0.57) | HTR2CMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL15436112 | 0.71 | HTR2C (0.46) | HTR2CSMN1; SMN2NPC1RAB9ACACNA1G | |
| SCHEMBL1766231 | 0.71 | HTR2C (0.60) | HTR2CMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL20353635 | 0.70 | FAAH (0.60) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326867-A2 | BRIDGED PIPERAZINE DERIVATIVES | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20020119961-A1 | Bridged piperazine derivatives | PFIZER INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002032901-A2 | BRIDGED PIPERAZINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119961-A1 | Bridged piperazine derivatives | MYD88, IL4, ARG1 | ALDH1A1 772/4885HTR2C 3590/4885MEN1 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.